Acurx Pharmaceuticals, Inc. (ACXP) stock
Close on Nov 13, 2026Market cap $5.06MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $5.06M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.69
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$8.10M
- EPS, diluted
- -$2.37
- Book value per share
- $1.38
- Diluted shares
- 5M
Trading
- Previous close
- $0.98
- Open
- $1.04
- Day's range
- $0.92 – $1.04
- Volume
- 223,472
- Average volume (20 days)
- 100,156
- Beta (5 years)
- -0.09
- 52-week range
- $0.92 – $7.54
- RSI (14 days)
- 32.9
- Volatility (1 year)
- 161.0%
- Relative volume
- 1.92×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACXP | S&P 500 | Difference | ACXP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.0% | -3.0% | −17.0 pts | ||
| 3 months | -35.1% | -2.8% | −32.4 pts | ||
| Year to date | -61.4% | +11.5% | −72.9 pts | ||
| 1 year | -79.7% | +13.5% | −93.2 pts | ||
| 3 years | -98.6% | +77.7% | −176.3 pts | -76.1% | +21.1% |
| 5 years | -99.0% | +72.6% | −171.6 pts | -60.5% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Acurx Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Results
- Results
About Acurx Pharmaceuticals
Pharmaceutical Preparations
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a novel class of small-molecule antibiotics to treat serious bacterial infections. Its development pipeline centers on antibiotic candidates that employ a Gram-positive selective spectrum approach to inhibit the bacterial enzyme DNA polymerase IIIC, which stops DNA replication and leads to cell death. The company's lead product candidate, ibezapolstat, targets Clostridioides difficile infections, while its earlier-stage candidate, ACX-375C, is being developed to address other resistant pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
Company profile, executives and historyAcurx Pharmaceuticals stock: common questions
What is Acurx Pharmaceuticals's stock price?
ACXP closed at $0.96 on Nov 13, 2026, down 2.54% on the day. Over the past 52 weeks it traded between $0.92 and $7.54.
What is Acurx Pharmaceuticals's market cap?
Acurx Pharmaceuticals was worth $5.06M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ACXP's P/E ratio?
Acurx Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.37), so it has no meaningful P/E ratio.
Does Acurx Pharmaceuticals pay a dividend?
No. Acurx Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has ACXP stock performed over the past year?
Including dividends, ACXP returned -79.7% over the past year, against +13.5% for the S&P 500.
How many ACXP shares are sold short?
0M shares were sold short at the latest FINRA report, 3.62% of the float, or 1.6 days of average trading volume.
Who are Acurx Pharmaceuticals's competitors?
Companies most similar to Acurx Pharmaceuticals by business, industry and size include ASMB, BCYC, MBRX, NRIX, COCP.
See a number that looks wrong?